達勁生技股份有限公司
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
1. "RaptDx" Disposable Chip-Based Quantitative PCR Device: Specially designed for rapid on-site testing, enabling molecular amplification and precise quantification of key biomarkers.
2. "EZDx" Non-Invasive cfDNA Liquid Biopsy System Device: Provides blood and saliva testing for tumor profiling to predict applicable targeted therapies.
(The content above was translated by AI.)
2. "EZDx" Non-Invasive cfDNA Liquid Biopsy System Device: Provides blood and saliva testing for tumor profiling to predict applicable targeted therapies.
(The content above was translated by AI.)
Founded Year
2023
Unified Business No.
28115334
Status
Active
Number of Employees
0
Total Paid-in
Capital
3,200,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Professor Dar-Bin Shieh of National Cheng Kung University is the founder of 達勁公司. The company develops a portable, rapid, and precise molecular Point of Care Testing (POCT) system, targeting primary care clinics, care institutions, and other facilities as its target market. This system enables early control of epidemics during pandemic periods, provides precision medicine to elderly high-risk groups to reduce severe illness, and utilizes POCT to reduce referrals for centralized testing, thereby relieving the burden on acute and critical care medical resources. The startup plans to research and develop solutions for respiratory diseases, mycoplasma pneumonia, gastrointestinal infections, sexually transmitted diseases, antimicrobial resistance monitoring, and oncology precision medicine to seize market growth opportunities. Its core technologies consist of magnetic nanoparticle capture, optoelectronic integrated chips, room-temperature reagents, and molecular diagnostic devices with mobile heating mechanisms.
(The content above was translated by AI.)
(The content above was translated by AI.)
